MAPT and Alzheimer disease: On the other hand, we detected a significant reduction of total tau levels in the soluble (S2) and crude synaptosome fractions (P2) of the hippocampus of 3xTg‐AD mice that received miR‐181a inhibitor (Figure 4k‐L).